What is the recommended treatment for an adult with bronchial asthma and chronic obstructive pulmonary disease (COPD)?

Treatment of Bronchial Asthma and COPD

For adults with both bronchial asthma and COPD (asthma-COPD overlap), initiate treatment with inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combination therapy as the foundation, following asthma treatment principles, with consideration for adding a long-acting muscarinic antagonist (LAMA) based on symptom burden and exacerbation risk. 1, 2, 3

Treatment Approach for Asthma-COPD Overlap

Primary Pharmacotherapy

• Start with ICS/LABA combination therapy as the cornerstone treatment, as this addresses the eosinophilic inflammation characteristic of asthma while providing bronchodilation 1, 3
• ICS should NOT be withheld in overlap patients, unlike pure COPD where ICS use is more restricted 2, 3
• The asthma component takes precedence in treatment decisions because untreated eosinophilic inflammation carries greater mortality risk 1

Escalation Strategy Based on Disease Severity

For patients with persistent symptoms or frequent exacerbations:

• Add LAMA to the ICS/LABA regimen, creating triple therapy (ICS/LABA/LAMA) 4
• Triple therapy is particularly indicated for patients with FEV1 <50% predicted and history of ≥2 exacerbations per year 4
• This combination addresses both the inflammatory (asthma) and hyperinflation/airflow limitation (COPD) components 2

For moderate disease with lower exacerbation risk:

• ICS/LABA remains the primary therapy 4
• LAMA monotherapy or LABA/LAMA combination are alternatives if ICS is refused or not tolerated, though this is suboptimal in overlap patients 4

Specific Medication Recommendations

Long-acting bronchodilators:

• LAMAs are superior to short-acting muscarinic antagonists for preventing moderate-to-severe exacerbations (Grade 1A recommendation) 4
• LABA/LAMA combinations show superior outcomes compared to single bronchodilators for symptom control 4

Inhaled corticosteroids:

• ICS/LABA combination reduces exacerbations more effectively than LABA monotherapy (Grade 1C) 4
• ICS/LABA shows mortality benefit compared to ICS monotherapy (Grade 1B) 4
• ICS monotherapy alone is NOT recommended for COPD or overlap patients 4

Important Caveats and Safety Considerations

Pneumonia risk:

• ICS therapy increases pneumonia risk by approximately 4% compared to bronchodilators alone 4
• This risk must be balanced against the exacerbation reduction benefits, particularly in overlap patients where ICS is more clearly indicated 4
• The pneumonia risk is lower with ICS/LABA combinations than previously thought in appropriately selected patients 4

Treatment hierarchy:

• In pure COPD (Group D), LABA/LAMA is preferred over ICS/LABA due to pneumonia concerns 4
• In asthma-COPD overlap, ICS/LABA takes priority, with LAMA added as needed 1, 2
• This distinction is critical: overlap patients should follow asthma guidelines primarily 1, 3

Additional Therapeutic Options

For patients with persistent exacerbations despite triple therapy:

• Consider roflumilast (PDE4 inhibitor) if FEV1 <50% predicted with chronic bronchitis phenotype and ≥1 hospitalization in the previous year 4
• Consider long-term macrolide therapy in former smokers, weighing risk of antibiotic resistance 4

Non-pharmacologic interventions:

• Pulmonary rehabilitation for patients with high symptom burden (groups B, C, D) 4
• Smoking cessation remains the single most important intervention 4
• Vaccination against influenza and pneumococcus 4

Monitoring and Adjustment

• Assess for reversibility with bronchodilators: >12% and >200 mL improvement in FEV1 confirms the asthma component 1
• Persistent baseline airflow limitation (FEV1/FVC <70%) that doesn't fully reverse confirms the COPD component 1
• If symptoms remain uncontrolled on ICS/LABA, escalate to triple therapy rather than increasing ICS dose alone 4

Key Clinical Pitfalls to Avoid

• Do not treat overlap patients as pure COPD by withholding ICS—this increases mortality risk 1, 3
• Do not use ICS monotherapy in any obstructive lung disease; always combine with long-acting bronchodilators 4
• Do not assume all patients with fixed obstruction have pure COPD—look for features of asthma including variability, atopy, and bronchodilator reversibility 1, 5
• Be cautious with fixed FEV1/FVC <70% cutoff in elderly patients as this may lead to COPD overdiagnosis 5